

ANSWERING REVIEWERS

October 20, 2012

Dear Editor,



Please find enclosed the edited manuscript in Word format (file name: 14027-review.doc).

Title: Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy

Author: Jung Gil Park, Soo Young Park, Hye Won Lee

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 14027

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) Reviewed by 00069920, More reference

We added two references about statistics of HCC (ref. 1) and dramatic response of sorafenib(ref. 6).

(2) Reviewed by 00502973

1. In Introduction: "However, only 30 to 40% of patients are diagnosed in the early stage HCC," change to "However, only 30 to 40% of patients are diagnosed in the early stage of HCC,"

We corrected that paragraph according to reviewer's recommendation

2. In Case Presentation: "A 59-year-old male patient was referred to Kyungpook National University Hospital for right upper quadrant of abdomen." The authors should present the complaint of the patient clearly, i.e. what happened in the right upper quadrant of abdomen of this patient.

We corrected that paragraph to "A 59-year-old male patient was referred to Kyungpook National University Hospital for evaluation of liver mass on abdominal ultrasound."

3. A picture of liver histology of the patient should be presented.

We added a picture of liver histology of the patient, figure 2

4. At the end of Case Presentation: "Post-RFA abdominal CT scan shows no enhancing lesions in liver with normalization of serum AFP and PIVKA-II levels." Change to "Post-RFA abdominal CT scan showed no enhancing lesions in liver with normalization of serum AFP and PIVKA-II levels."

We corrected that paragraph according to reviewer's recommendation

5. Last paragraph of Discussion: "In conclusion, this report demonstrates the possible role of sorafenib to downstage advanced HCC for locoregional therapy achieving complete remission." Change to "In conclusion, this report demonstrates the possible role of sorafenib to downstage advanced HCC for

locoregional therapy achieving complete remission.”

We corrected that paragraph according to reviewer’s recommendation

6. Fig. 1A, 1B, 1C and 1D should be combined. Same comment to Fig. 3.

We corrected that paragraph according to reviewer’s recommendation

7. In Fig. 2, the authors depicted tumor size by RECIST 1.1 or mRECIST. But there were no description in the text. The authors should presented how these numbers were obtained.

We mentioned tumor size at this paragraph “In contrast to serum PIVKA-II level and tumor size which remained stable, serum AFP level started to increase in 6 months after sorafenib therapy (Figure. 3).” Also, we corrected legend of Figure 3 to “Clinical course and serial changes of patient’s serum level of α -feto protein, PIVKA-II and tumor size accessed by RECIST and mRECIST.”

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Soo Young Park, MD, PhD

Division of Gastroenterology and Hepatology

Department of Internal Medicine

Kyungpook National University Hospital

130 Dongdeok-ro, Jung-gu, Daegu, 700-721, Republic of Korea.

Tel.: +82-53-2005519; fax: +82-53-4268773,

E-mail: psyoun0419@gmail.com